• About
  • Advertise
  • Contact
  • Categories
  • Archives
    • Around the Market (5)
    • Blog (3)
    • Featured (5)
    • Forex (1)
    • News (26)
    • April 2011 (3)
    • March 2011 (29)
ad
Active Investor
  • Popular
  • Recent
  • Comments
    • 35 High-Quality Vector Characters Downloads
      Feb 20th - 4 Comments
    • Hello world!
      Mar 7th - 1 Comments
    • Sample Page
      Mar 7th - 0 Comments
    • Flotek Announces 2010 Fiscal Results
      Mar 17th - 0 Comments
    • Expedia Shares Rise on News of Split
      Apr 8th - 0 Comments
    • Epicor Software Corporation Shares Climb on Buyout News
      Apr 4th - 0 Comments
    • McCormick and Schmick’s Rise as Buyout Looms
      Apr 4th - 0 Comments
    • Cephalon Shares Jump on Hostile Takeover Bid
      Mar 30th - 0 Comments

    Mar 23rd

    XOMA’s Diabetes Drug Fails in Trial

    XOMA is down over 30% this morning after the company announced their diabetes drug failed to lower blood sugar. The company said that a random group of people with Type 2 diabetes from a pool of over 400 were treated with their diabetes drug over the course of six months. At the end of the trial, the people who received the drug showed no reduction in blood sugar levels than those taking placebos.

    XOMA did note however that the trial showed significant declines in C-reactive protein, which is a sign for risk of heart attack, stroke, and other cardiovascular diseases. The company also stated, “The safety and tolerability profile in this population was consistent with previous XOMA 052 clinical trials, and there were no serious drug-related adverse events.” XOMA also said they expect to take the drug into clinical development for cardiovascular diseases next year.

    The stock is currently trading down $1.48 at $3.54 and has traded nearly 4 million shares already today.

    About XOMA

    XOMA is at the forefront of antibody discovery and development, one of the most powerful and transformative fields of drug innovation today. Building on a pioneering proprietary pipeline, a world-class antibody discovery and development platform, plus multiple revenue streams, XOMA is creating innovative human antibody therapeutics with the potential to transform medicine and reshape people’s lives.

    There are no responses so far.

    Leave your response:

    Click here to cancel reply.

    Copyright 2008-2022. All Rights Reserved DDStudios.